Alterity Therapeutics Announces Share Consolidation/Split

Alterity Therapeutics Limited, a development-stage biotechnology company, filed a Form 6-K with the SEC on April 30, 2026, announcing a consolidation or split of its ordinary shares (Ticker: ATH). The filing includes Exhibit 99.1, which details the terms of the share consolidation/split. This corporate action is typically undertaken to adjust the company\'s share price or capital structure and is being incorporated by reference into the company\'s existing Registration Statements on Form S-8 and Form F-3. The document was signed by Julian Babarczy, Chairman of the Board. No specific clinical trial data or updates regarding the company\'s lead candidates for neurodegenerative diseases were included in this specific administrative filing. The move reflects standard capital management practices for foreign private issuers listed on U.S. exchanges.